Tom 14, Nr 4 (2019)
Artykuł przeglądowy
Opublikowany online: 2019-08-31
Wyświetlenia strony
650
Wyświetlenia/pobrania artykułu
828
Preparat złożony atorwastatyna/perindopril — nowoczesna prewencja zdarzeń sercowo-naczyniowych
DOI: 10.5603/FC.2019.0095
Folia Cardiologica 2019;14(4):368-375.
Streszczenie
Choroby układu sercowo-naczyniowego są główną przyczyną zgonów w Polsce, a najczęściej występujące czynniki ryzyka sercowo-naczyniowego to dyslipidemia i nadciśnienie tętnicze. Niestety odsetek chorych z dobrze kontrolowaną dyslipidemią i nadciśnieniem tętniczym pozostaje bardzo niski. Wynika on głównie z niedostatecznej terapii statynami. Perindopril i atorwastatyna to substancje o udokumentowanym wpływie na ograniczenie częstości występowania zdarzeń sercowo-naczyniowych. Zastosowanie tych leków w jednej tabletce może spowodować istotny wzrost odsetka chorych właściwie leczonych i osiągających docelowe wartości ciśnienia tętniczego i cholesterolu frakcji LDL.
Słowa kluczowe: nadciśnienie tętniczehipercholesterolemiaperindoprilatorwastatynaleczenie skojarzone
Referencje
- Nichols M, Townsend N, Scarborough P, et al. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014; 35(42): 2950–2959.
- Lawes CMM, Vander Hoorn S, Rodgers A, et al. International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008; 371(9623): 1513–1518.
- Zdrojewski Ł, Zdrojewski T, Rutkowski M, et al. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol. 2013; 71(4): 381–392.
- Bandosz P, O'Flaherty M, Drygas W, et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ. 2012; 344: d8136.
- Czarnecka D, Stolarz-Skrzypek K, Bednarski A, et al. Therapeutic strategies in poorly controlled hypertension in outpatient setting in Poland — POSTER study. Folia Cardiol. 2015; 10(4): 242–248.
- Dalal JJ, Padmanabhan TNC, Jain P, et al. LIPITENSION: Interplay between dyslipidemia and hypertension. Indian J Endocrinol Metab. 2012; 16(2): 240–245.
- Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.
- Tykarski A, Filipiak KJ, Januszewicz A, et al. Zasady postępowania w nadciśnieniu tętniczym — 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1–84.
- Sulicka J, Fornal M, Gryglewska B, et al. Selected cardiovascular risk factors in primary care patients. Arterial Hypertens. 2006; 10: 370–376.
- Montalescot G, Sechtem U, Achenbach S, et al. Task Force Members, ESC Committee for Practice Guidelines, Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38): 2949–3003.
- van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012; 33(16): 2088–2097.
- Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013; 61(2): 131–142.
- Choi InS, Park IeB, Lee K, et al. Korea Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH) investigators. Angiotensin-converting enzyme inhibitors provide better long-term survival benefits to patients with AMI than angiotensin II receptor blockers after survival hospital discharge. J Cardiovasc Pharmacol Ther. 2018 [Epub ahead of print]: 1074248418795897.
- Brugts JJ, van Vark L, Akkerhuis M, et al. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis. Int J Cardiol. 2015; 181: 425–429.
- Dahlöf B, Sever P, Poulter N, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet. 2005; 366(9489): 895–906.
- Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887–1898.
- Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. The Lancet. 2007; 370(9590): 829–840.
- Ceconi C, Francolini G, Olivares A, et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007; 577(1-3): 1–6.
- Asmar R, Topouchian J, Pannier B, et al. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. J Hypertens. 2001; 19(4): 813–818.
- Bots ML, Remme WJ, Lüscher TF, et al. EUROPA-PERFECT Investigators. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther. 2007; 21(4): 269–279.
- Dinicolantonio JJ, Lavie CJ, O'Keefe JH. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Postgrad Med. 2013; 125(4): 154–168.
- Sever P, Dahlöf B, Poulter N, et al. ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006; 27(24): 2982–2988.
- Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127–1137.
- Zdrojewski T, Solnica B, Cybulska B, et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016; 74(3): 213–223.
- Kotseva K, Wood D, Backer GDe, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. The Lancet. 2009; 373(9667): 929–940.
- Prejbisz A, Klocek M, Gąsowski J, et al. Factors associated with resistant hypertension in a large cohort of hypertensive patients: the Pol-Fokus study. Pol Arch Med Wewn. 2015; 125(4): 249–259.
- Wiśniowska B, Skowron A. Evaluation of patients' adherence to statins in Poland. Curr Med Res Opin. 2011; 27(1): 99–105.
- Chapman RH, Benner JS, Girase P, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147–1152.
- Agarwal S, Tang SSK, Rosenberg N, et al. Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy? Am J Ther. 2009; 16(2): 119–126.
- Awad K, Serban MC, Penson P, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. J Clin Lipidol. 2017; 11(4): 972–985.e9.
- Euvascor. Charakterystyka Produktu Leczniczego 07/2019. https://webcache.googleusercontent.com/search?q=cache:xn87WRWfxN0J:https://pub.rejestrymedyczne.csioz.gov.pl/Pobieranie.ashx%3Ftype%3D38135-c+&cd=1&hl=pl&ct=clnk&gl=pl (21.08.2019).
